Currently, Toku's BioAge™ is a wellness tool focused on health awareness, while CLAiR™ is still in development and expected to seek FDA approval in 2026.

Individuals undergoing BioAge™ analysis will be connected to Lifeforce's platform, which offers at-home diagnostics, access to expert physicians, and personalized health protocols.

Lifeforce reports that 85 percent of its members see improvements in quality of life and health outcomes within six months of using their services.

Lifeforce, the world's largest longevity medicine platform, has partnered with Toku, a health tech company specializing in AI retinal imaging, to improve cardiovascular risk assessment and aging insights.

This collaboration will leverage Toku's BioAge™ product and the upcoming CLAiR™ technology, which has received FDA Breakthrough Device designation, to turn routine eye exams into early health intervention opportunities.

The partnership aims to utilize retinal imaging to assess biological age and cardiovascular risks non-invasively, transforming routine eye exams into opportunities for early health intervention.

Dugal Bain-Kim, CEO of Lifeforce, emphasized the importance of acting on health data to drive lifestyle changes, while Toku's CEO Ehsan Vaghefi highlighted the partnership's role in enabling proactive health management.